Skip to main content
Top
Published in: Journal of Clinical Immunology 3/2009

01-05-2009

Polymorphisms of PTPN11 Coding SHP-2 as Biomarkers for Ulcerative Colitis Susceptibility in the Japanese Population

Authors: Yukiko Narumi, Hajime Isomoto, Mizuho Shiota, Kayoko Sato, Shinji Kondo, Haruhisa Machida, Katsunori Yanagihara, Yohei Mizuta, Shigeru Kohno, Kazuhiro Tsukamoto

Published in: Journal of Clinical Immunology | Issue 3/2009

Login to get access

Abstract

Objective

To identify genetic determinants of inflammatory bowel disease (IBD), we examined an association between polymorphisms of both the programmed cell death 1 gene (PDCD1) and the src homology 2 domain-containing tyrosine phosphatase 2 gene (PTPN11) and susceptibility to IBD.

Methods

Study subjects comprised 114 patients with ulcerative colitis (UC), 83 patients with Crohn’s disease, and 200 healthy control subjects. Five single nucleotide polymorphisms (SNPs) in PDCD1 and PTPN11 were detected by polymerase chain reaction restriction fragment length polymorphism. Subsequently, haplotypes composed of the two SNPs in PTPN11 were constructed.

Results

The frequencies of the Hap 1 haplotype and its homozygous Hap 1/Hap 1 diplotype of PTPN11 were significantly increased in UC patients compared to control subjects (P = 0.011 and P = 0.030, respectively). While no association was found for PDCD1 for UC or CD and none for PTPN11 for CD.

Conclusion

PTPN11 is a genetic determinant for the pathogenesis of UC, and haplotyping of PTPN11 may be useful as a genetic biomarker to identify high-risk individuals susceptible to UC.
Literature
10.
go back to reference Machida H, Tsukamoto K, Wen CY, Narumi Y, Shikuwa S, Isomoto H, et al. Association of polymorphic alleles of CTLA4 with inflammatory bowel disease in the Japanese. World J Gastroenterol 2005;11:4188–93.PubMed Machida H, Tsukamoto K, Wen CY, Narumi Y, Shikuwa S, Isomoto H, et al. Association of polymorphic alleles of CTLA4 with inflammatory bowel disease in the Japanese. World J Gastroenterol 2005;11:4188–93.PubMed
15.
go back to reference Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibit T cell activation. Nat Immunol 2001;2:261–8. doi:10.1038/85330.PubMedCrossRef Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibit T cell activation. Nat Immunol 2001;2:261–8. doi:10.​1038/​85330.PubMedCrossRef
16.
go back to reference Prokunina L, Castillejo-López C, Öberg F, Gunnarsson I, Berg L, Magnusson V, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002;32:666–9. doi:10.1038/ng1020.PubMedCrossRef Prokunina L, Castillejo-López C, Öberg F, Gunnarsson I, Berg L, Magnusson V, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002;32:666–9. doi:10.​1038/​ng1020.PubMedCrossRef
17.
go back to reference Ferreiros-Vidal I, Gomez-Reino JJ, Barros F, Carracedo A, Carreira P, Gonzalez-Escribano F, et al. Association of PDCD1 with susceptibility to systemic lupus erythematosus: evidence of population-specific effects. Arthritis Rheum 2004;50:2590–7. doi:10.1002/art.20436.PubMedCrossRef Ferreiros-Vidal I, Gomez-Reino JJ, Barros F, Carracedo A, Carreira P, Gonzalez-Escribano F, et al. Association of PDCD1 with susceptibility to systemic lupus erythematosus: evidence of population-specific effects. Arthritis Rheum 2004;50:2590–7. doi:10.​1002/​art.​20436.PubMedCrossRef
18.
go back to reference Johansson M, Ärlestig L, Möller B, Rantapää-Dahlqvist S. Association of a PDCD1 polymorphism with renal manifestations in systemic lupus erythematosus. Arthritis Rheum 2005;52:1665–9. doi:10.1002/art.21058.PubMedCrossRef Johansson M, Ärlestig L, Möller B, Rantapää-Dahlqvist S. Association of a PDCD1 polymorphism with renal manifestations in systemic lupus erythematosus. Arthritis Rheum 2005;52:1665–9. doi:10.​1002/​art.​21058.PubMedCrossRef
19.
go back to reference Lin SC, Yen JH, Tsai JJ, Tsai WC, Ou TT, Liu HW, et al. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum 2004;50:770–5. doi:10.1002/art.20040.PubMedCrossRef Lin SC, Yen JH, Tsai JJ, Tsai WC, Ou TT, Liu HW, et al. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum 2004;50:770–5. doi:10.​1002/​art.​20040.PubMedCrossRef
20.
go back to reference Kong EKP, Prokunina-Olsson L, Wong WHS, Lau CS, Chan TM, Alarcón-Riquelme M, et al. A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum 2005;52:1058–62. doi:10.1002/art.20966.PubMedCrossRef Kong EKP, Prokunina-Olsson L, Wong WHS, Lau CS, Chan TM, Alarcón-Riquelme M, et al. A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum 2005;52:1058–62. doi:10.​1002/​art.​20966.PubMedCrossRef
21.
go back to reference Kroner A, Mehling M, Hemmer B, Riechmann P, Toyka KV, Mäurer M, et al. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 2005;58:50–7. doi:10.1002/ana.20514.PubMedCrossRef Kroner A, Mehling M, Hemmer B, Riechmann P, Toyka KV, Mäurer M, et al. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 2005;58:50–7. doi:10.​1002/​ana.​20514.PubMedCrossRef
22.
go back to reference Chuang E, Lee KM, Robbins MD, Duerr JM, Alegre ML, Hambor JE, et al. Regulation of cytotoxic T lymphocyte-associated molecule-4 by src kinases. J Immunol 1999;162:1270–7.PubMed Chuang E, Lee KM, Robbins MD, Duerr JM, Alegre ML, Hambor JE, et al. Regulation of cytotoxic T lymphocyte-associated molecule-4 by src kinases. J Immunol 1999;162:1270–7.PubMed
24.
go back to reference Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 2001;98:13866–71. doi:10.1073/pnas.231486598.PubMedCrossRef Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 2001;98:13866–71. doi:10.​1073/​pnas.​231486598.PubMedCrossRef
25.
go back to reference Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004;173:945–54.PubMed Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004;173:945–54.PubMed
26.
go back to reference Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001;29:465–8. doi:10.1038/ng772.PubMedCrossRef Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001;29:465–8. doi:10.​1038/​ng772.PubMedCrossRef
27.
go back to reference Digilio MC, Conti E, Sarkozy A, Migarelli R, Dottorini T, Marino B, et al. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 2002;71:389–94. doi:10.1086/341528.PubMedCrossRef Digilio MC, Conti E, Sarkozy A, Migarelli R, Dottorini T, Marino B, et al. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 2002;71:389–94. doi:10.​1086/​341528.PubMedCrossRef
28.
29.
go back to reference Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, et al. Somatic mutations in PTPN11 in juvenile myelomonocyte leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003;34:148–50. doi:10.1038/ng1156.PubMedCrossRef Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, et al. Somatic mutations in PTPN11 in juvenile myelomonocyte leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003;34:148–50. doi:10.​1038/​ng1156.PubMedCrossRef
30.
go back to reference Goto Y, Ando T, Yamamoto K, Tamakoshi A, El-Omar E, Goto H, et al. Association between serum pepsinogens and polymorphism of PTPN11 encoding SHP-2 among Helicobacter pylori seropositive Japanese. Int J Cancer 2006;118:203–8. doi:10.1002/ijc.21338.PubMedCrossRef Goto Y, Ando T, Yamamoto K, Tamakoshi A, El-Omar E, Goto H, et al. Association between serum pepsinogens and polymorphism of PTPN11 encoding SHP-2 among Helicobacter pylori seropositive Japanese. Int J Cancer 2006;118:203–8. doi:10.​1002/​ijc.​21338.PubMedCrossRef
31.
go back to reference Podolsky DK. Inflammatory bowel disease (1). N Engl J Med 1991;325:928–37.PubMed Podolsky DK. Inflammatory bowel disease (1). N Engl J Med 1991;325:928–37.PubMed
32.
go back to reference Podolsky DK. Inflammatory bowel disease (2). N Engl J Med 1991;325:1008–16.PubMed Podolsky DK. Inflammatory bowel disease (2). N Engl J Med 1991;325:1008–16.PubMed
36.
go back to reference Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334:297–314.PubMed Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334:297–314.PubMed
40.
go back to reference Carey R, Jurickova I, Ballard E, Bonkowski E, Han X, Xu H, et al. Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease. Inflamm Bowel Dis 2008;14:446–57. doi:10.1002/ibd.20342.PubMedCrossRef Carey R, Jurickova I, Ballard E, Bonkowski E, Han X, Xu H, et al. Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease. Inflamm Bowel Dis 2008;14:446–57. doi:10.​1002/​ibd.​20342.PubMedCrossRef
41.
44.
go back to reference Oishi K, Gaengel K, Krishnamoorthy S, Kamiya K, Kim IK, Ying H, et al. Transgenic Drosophila models of Noonan syndrome causing PTPN11 gain-of-function mutations. Hum Mol Genet 2006;15:543–53. doi:10.1093/hmg/ddi471.PubMedCrossRef Oishi K, Gaengel K, Krishnamoorthy S, Kamiya K, Kim IK, Ying H, et al. Transgenic Drosophila models of Noonan syndrome causing PTPN11 gain-of-function mutations. Hum Mol Genet 2006;15:543–53. doi:10.​1093/​hmg/​ddi471.PubMedCrossRef
Metadata
Title
Polymorphisms of PTPN11 Coding SHP-2 as Biomarkers for Ulcerative Colitis Susceptibility in the Japanese Population
Authors
Yukiko Narumi
Hajime Isomoto
Mizuho Shiota
Kayoko Sato
Shinji Kondo
Haruhisa Machida
Katsunori Yanagihara
Yohei Mizuta
Shigeru Kohno
Kazuhiro Tsukamoto
Publication date
01-05-2009
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 3/2009
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-008-9272-6

Other articles of this Issue 3/2009

Journal of Clinical Immunology 3/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.